Centene stock remains anchored by Medicaid scale and earnings

Centene Corp. (US15133V1035) remains a large-cap managed-care name with 2025 premium and service revenues of $163.1 billion, adjusted diluted EPS of $7.11, and a medical cost ratio of 87.9%. The company also finished 2025 with a health benefits ratio of 87.9% and a total of 28.7 million members across its government-sponsored programs and commercial business.

Revenue stays above $160 billion

Centene reported premium and service revenues of $163.1 billion for fiscal 2025, a scale figure that puts the insurer among the biggest U.S. managed-care groups. The same period included adjusted diluted EPS of $7.11, which gives investors a clearer earnings reference point than the headline net result.

That earnings level came after Centene generated net income attributable to common stockholders of $3.8 billion for 2025, compared with a net loss of $1.8 billion in 2024. The year-over-year swing is the most important comparison in the latest reported figures because it shows how sharply profitability recovered in the period.

Margins and medical costs

The company said its medical cost ratio was 87.9% for 2025, which remained the key operating yardstick for margin discipline. In managed care, a lower ratio generally leaves more room for administrative costs and profit, so the 2025 level matters as much as the top-line growth.

Centene also reported 28.7 million members at year-end 2025. That membership base helps explain why the company can absorb changes in reimbursement, state contract dynamics, and utilization trends across Medicaid, Medicare, the exchanges, and specialty programs.

Government programs drive the scale

Centene built its model around publicly funded health coverage, and the 2025 numbers still reflect that focus. The company said government-sponsored programs remained the main engine behind its membership and revenue base, while specialty services added another layer of diversification.

For investors, the important detail is not only the size of the franchise but also the spread of earnings across lines of business. A 2025 EPS result of $7.11 after a 2024 loss is a cleaner signal than any single quarter can provide.

Medicaid remains the core

Centene's Medicaid exposure is still the central product story because it explains the scale, the margins, and the sensitivity to state-level rate changes. The company's government-program footprint also gives it a broad claims and enrollment base that few U.S. peers can match.

That scale shows up in the reported 28.7 million total members at the end of 2025 and in the $163.1 billion revenue base for the full year. Those two numbers, taken together, describe a business that is both very large and heavily tied to reimbursement trends.

Latest reported level

Centene stock closed the latest available reference period at a valuation tied to the company's 2025 operating base, with the reported numbers above providing the clearest current anchor for the share story. The latest market context should be read against the 2025 revenue of $163.1 billion, EPS of $7.11, and medical cost ratio of 87.9%.